The EPS beat and reduced cash burn are mildly positive, but the dilutive equity plan and pre-revenue status limit upside. Monitor upcoming ASCO data and FDA guidance in 2H26 for pipeline catalysts.
Price Chart
Executive Summary
IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by lower R&D expenses. Cash stood at $21.9M. Shareholders approved the 2026 equity incentive plan, adding 2.92M shares for future grants. The clinical pipeline continues with GBM data and TCE platform milestones expected in 2026.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $5.1M, improved from $5.6M YoY
- EPS of -$0.26 beat consensus of -$0.59 by 56%
- Cash $21.9M as of March 31, 2026 (down from $27.1M at Dec 2025)
- Shareholders approved 2026 equity plan, adding 2.92M new shares
- R&D expenses decreased to $2.6M from $3.0M YoY
- Upcoming ASCO presentation on updated GBM overall survival data
Financial Impact
Q1 net loss $5.1M vs $5.6M YoY improvement; EPS -$0.26 versus -$2.16 prior (adjusted for reverse split).
Risk Factors
- Cash burn rate: $5.1M/quarter implies runway of ~1 year at current spend
- Dilution from 2.92M new shares under the 2026 equity plan
- No approved products or revenue, entirely dependent on pipeline success
- Potential capital needs may require further dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-212128 |
| Document: inab-ex99_1.htm | 0001193125-26-212128 |
| Document: inab-20260507.htm | 0001193125-26-212128 |
| Document: inab-ex10_2.htm | 0001193125-26-212128 |
| Document: 0001193125-26-212128-index-headers.html | 0001193125-26-212128 |
| Document: 0001193125-26-212128-index.html | 0001193125-26-212128 |
| Document: 0001193125-26-212128.txt | 0001193125-26-212128 |
| 8-K Data (Synthetic) | 0001193125-26-212128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9655 (−37.31%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
May 18, 2026 22w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9655 (+33.41%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9655 (−38.89%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9655 (−31.52%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9655 (−48.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers